vs
RANGE RESOURCES CORP（RRC）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
RANGE RESOURCES CORP的季度营收约是Revvity的1.0倍（$786.9M vs $772.1M），RANGE RESOURCES CORP净利率更高（22.8% vs 12.7%，领先10.0%），RANGE RESOURCES CORP同比增速更快（18.0% vs 5.9%），过去两年RANGE RESOURCES CORP的营收复合增速更高（14.6% vs 9.0%）
Range Resources Corporation是一家总部位于美国得克萨斯州沃斯堡的天然气勘探开采企业，核心运营区域为马塞勒斯页岩地层，是该地区拥有土地面积最大的运营商，专注于天然气资源的勘探、开发与生产业务，在北美油气开发领域具备深厚的行业积累。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
RRC vs RVTY — 直观对比
营收规模更大
RRC
是对方的1.0倍
$772.1M
营收增速更快
RRC
高出12.1%
5.9%
净利率更高
RRC
高出10.0%
12.7%
两年增速更快
RRC
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $786.9M | $772.1M |
| 净利润 | $179.1M | $98.4M |
| 毛利率 | 94.5% | — |
| 营业利润率 | — | 14.5% |
| 净利率 | 22.8% | 12.7% |
| 营收同比 | 18.0% | 5.9% |
| 净利润同比 | 88.8% | 3.9% |
| 每股收益（稀释后） | $0.75 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收RRCRVTY
| Q4 25 | $786.9M | $772.1M | ||
| Q3 25 | $655.3M | $698.9M | ||
| Q2 25 | $699.6M | $720.3M | ||
| Q1 25 | $846.3M | $664.8M | ||
| Q4 24 | $667.0M | $729.4M | ||
| Q3 24 | $567.9M | $684.0M | ||
| Q2 24 | $513.2M | $691.7M | ||
| Q1 24 | $598.8M | $649.9M |
净利润RRCRVTY
| Q4 25 | $179.1M | $98.4M | ||
| Q3 25 | $144.3M | $46.7M | ||
| Q2 25 | $237.6M | $53.9M | ||
| Q1 25 | $97.1M | $42.2M | ||
| Q4 24 | $94.8M | $94.6M | ||
| Q3 24 | $50.7M | $94.4M | ||
| Q2 24 | $28.7M | $55.4M | ||
| Q1 24 | $92.1M | $26.0M |
毛利率RRCRVTY
| Q4 25 | 94.5% | — | ||
| Q3 25 | 92.5% | 53.6% | ||
| Q2 25 | 95.0% | 54.5% | ||
| Q1 25 | 93.1% | 56.5% | ||
| Q4 24 | 93.7% | — | ||
| Q3 24 | 94.3% | 56.3% | ||
| Q2 24 | 93.4% | 55.7% | ||
| Q1 24 | 94.7% | 54.6% |
营业利润率RRCRVTY
| Q4 25 | — | 14.5% | ||
| Q3 25 | — | 11.7% | ||
| Q2 25 | — | 12.6% | ||
| Q1 25 | — | 10.9% | ||
| Q4 24 | — | 16.3% | ||
| Q3 24 | — | 14.3% | ||
| Q2 24 | — | 12.4% | ||
| Q1 24 | — | 6.8% |
净利率RRCRVTY
| Q4 25 | 22.8% | 12.7% | ||
| Q3 25 | 22.0% | 6.7% | ||
| Q2 25 | 34.0% | 7.5% | ||
| Q1 25 | 11.5% | 6.4% | ||
| Q4 24 | 14.2% | 13.0% | ||
| Q3 24 | 8.9% | 13.8% | ||
| Q2 24 | 5.6% | 8.0% | ||
| Q1 24 | 15.4% | 4.0% |
每股收益（稀释后）RRCRVTY
| Q4 25 | $0.75 | $0.86 | ||
| Q3 25 | $0.60 | $0.40 | ||
| Q2 25 | $0.99 | $0.46 | ||
| Q1 25 | $0.40 | $0.35 | ||
| Q4 24 | $0.38 | $0.77 | ||
| Q3 24 | $0.21 | $0.77 | ||
| Q2 24 | $0.12 | $0.45 | ||
| Q1 24 | $0.38 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $204.0K | $919.9M |
| 总债务越低越好 | $1.2B | — |
| 股东权益账面价值 | $4.3B | $7.3B |
| 总资产 | $7.4B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.28× | — |
8季度趋势，按日历期对齐
现金及短期投资RRCRVTY
| Q4 25 | $204.0K | $919.9M | ||
| Q3 25 | $175.0K | $931.4M | ||
| Q2 25 | $134.0K | $991.8M | ||
| Q1 25 | $344.6M | $1.1B | ||
| Q4 24 | $304.5M | $1.2B | ||
| Q3 24 | $277.4M | $1.2B | ||
| Q2 24 | $251.1M | $2.0B | ||
| Q1 24 | $343.1M | $1.7B |
总债务RRCRVTY
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.7B | — | ||
| Q4 24 | $1.7B | — | ||
| Q3 24 | $1.7B | — | ||
| Q2 24 | $1.7B | — | ||
| Q1 24 | $1.8B | — |
股东权益RRCRVTY
| Q4 25 | $4.3B | $7.3B | ||
| Q3 25 | $4.2B | $7.4B | ||
| Q2 25 | $4.1B | $7.6B | ||
| Q1 25 | $3.9B | $7.6B | ||
| Q4 24 | $3.9B | $7.7B | ||
| Q3 24 | $3.9B | $7.9B | ||
| Q2 24 | $3.9B | $7.9B | ||
| Q1 24 | $3.8B | $7.8B |
总资产RRCRVTY
| Q4 25 | $7.4B | $12.2B | ||
| Q3 25 | $7.2B | $12.1B | ||
| Q2 25 | $7.1B | $12.4B | ||
| Q1 25 | $7.4B | $12.4B | ||
| Q4 24 | $7.3B | $12.4B | ||
| Q3 24 | $7.2B | $12.8B | ||
| Q2 24 | $7.3B | $13.4B | ||
| Q1 24 | $7.4B | $13.4B |
负债/权益比RRCRVTY
| Q4 25 | 0.28× | — | ||
| Q3 25 | 0.29× | — | ||
| Q2 25 | 0.29× | — | ||
| Q1 25 | 0.43× | — | ||
| Q4 24 | 0.43× | — | ||
| Q3 24 | 0.44× | — | ||
| Q2 24 | 0.44× | — | ||
| Q1 24 | 0.46× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $257.5M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | 1.44× | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流RRCRVTY
| Q4 25 | $257.5M | $182.0M | ||
| Q3 25 | $247.5M | $138.5M | ||
| Q2 25 | $336.2M | $134.3M | ||
| Q1 25 | $330.1M | $128.2M | ||
| Q4 24 | $217.9M | $174.2M | ||
| Q3 24 | $245.9M | $147.9M | ||
| Q2 24 | $148.8M | $158.6M | ||
| Q1 24 | $331.9M | $147.6M |
自由现金流RRCRVTY
| Q4 25 | — | $161.8M | ||
| Q3 25 | — | $120.0M | ||
| Q2 25 | — | $115.5M | ||
| Q1 25 | — | $112.2M | ||
| Q4 24 | — | $149.8M | ||
| Q3 24 | — | $125.6M | ||
| Q2 24 | — | $136.6M | ||
| Q1 24 | — | $129.7M |
自由现金流率RRCRVTY
| Q4 25 | — | 21.0% | ||
| Q3 25 | — | 17.2% | ||
| Q2 25 | — | 16.0% | ||
| Q1 25 | — | 16.9% | ||
| Q4 24 | — | 20.5% | ||
| Q3 24 | — | 18.4% | ||
| Q2 24 | — | 19.7% | ||
| Q1 24 | — | 20.0% |
资本支出强度RRCRVTY
| Q4 25 | — | 2.6% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | — | 3.4% | ||
| Q3 24 | — | 3.3% | ||
| Q2 24 | — | 3.2% | ||
| Q1 24 | — | 2.7% |
现金转化率RRCRVTY
| Q4 25 | 1.44× | 1.85× | ||
| Q3 25 | 1.72× | 2.97× | ||
| Q2 25 | 1.42× | 2.49× | ||
| Q1 25 | 3.40× | 3.03× | ||
| Q4 24 | 2.30× | 1.84× | ||
| Q3 24 | 4.85× | 1.57× | ||
| Q2 24 | 5.18× | 2.87× | ||
| Q1 24 | 3.60× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
RRC
| Natural Gas Natural Gas Liquids And Oil Sales | $745.5M | 95% |
| Brokered Natural Gas And Marketing | $41.3M | 5% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
